Kissei Pharmaceutical Co., Ltd Company Review & Valuation KSPHF
About Kissei Pharmaceutical Co., Ltd
Kissei Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in Japan. It offers Urief and OD tablets for the treatment of dysuria; Glufast and Glubes tablets for diabetes; Epoetin Alfa BS injection for the treatment of renal anemia; P-TOL chewable tablets for treating hyperphosphatemia in patients on dialysis; Mitiglinide for treating Type 2 diabetes mellitus; and RECTABUL, a rectal foam product for the treatment of ulcerative colitis. The company's product pipeline includes KPS-0373 that is in Phase III clinical trials for spinocerebellar ataxia; AJM300, which is in Phase III clinical trials for ulcerative colitis; YS110, which is in Phase I/II clinical trials for Malignant mesothelioma; and JR-131 that is in NDA preparation for renal anemia. It is also developing KLH-2109, which is in Phase II clinical trials for treating endometriosis and uterine fibroids; KDT-3594 that is in Phase I clinical trials for Parkinson's disease; MR13A9 that is in Phase II clinical trials for uremic pruritus in dialysis patients; and CCX168, which is in Phase I clinical trials for the treatment of anti-neutrophil cytoplasmic auto-antibody associated vasculitis. In addition, the company is developing Bedoradrine that is in Phase I clinical trials for the treatment of acute exacerbation of asthma; and Phase II clinical trials for the treatment of COPD, as well as provides information solution and construction subcontracting services. Additionally, it develops and sells protein controlled and energy supply foods. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was founded in 1946 and is headquartered in Matsumoto, Japan.
- Drug Manufacturers - Specialty & Generic
- Matsumoto, Japan
Primary Stock Exchange Listings